Cargando…

Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go?

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multi-systemic involvement. Nervous system involvement in SLE leads to a series of uncommon and heterogeneous neuropsychiatric (NP) manifestations. Current knowledge on the underlying pathogenic processes and their s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magro-Checa, César, Steup-Beekman, Gerda M., Huizinga, Tom W., van Buchem, Mark A., Ronen, Itamar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288259/ https://www.ncbi.nlm.nih.gov/pubmed/30564579 http://dx.doi.org/10.3389/fmed.2018.00340

Ejemplares similares

Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives
por: Magro-Checa, César, et al.
Publicado: (2016)

Different phenotypes of neuropsychiatric systemic lupus erythematosus are related to a distinct pattern of structural changes on brain MRI
por: Inglese, Francesca, et al.
Publicado: (2021)

Quantitative susceptibility mapping in the thalamus and basal ganglia of systemic lupus erythematosus patients with neuropsychiatric complaints
por: Bulk, Marjolein, et al.
Publicado: (2021)

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

MRI-Based Classification of Neuropsychiatric Systemic Lupus Erythematosus Patients With Self-Supervised Contrastive Learning
por: Inglese, Francesca, et al.
Publicado: (2022)

Neuropsychiatric systemic lupus erythematosus is associated with a distinct type and shape of cerebral white matter hyperintensities
por: Inglese, Francesca, et al.
Publicado: (2021)

C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus
por: van Schaarenburg, Rosanne A., et al.
Publicado: (2016)

A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus
por: Ercan, Ece, et al.
Publicado: (2015)

Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of life
por: Monahan, R C, et al.
Publicado: (2017)

Selective Involvement of the Amygdala in Systemic Lupus Erythematosus
por: Emmer, Bart J, et al.
Publicado: (2006)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort
por: Magro-Checa, C., et al.
Publicado: (2018)

Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus
por: Steens, Stefan CA, et al.
Publicado: (2006)

The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
por: Piga, Matteo, et al.
Publicado: (2021)

Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus
por: Mackay, Meggan, et al.
Publicado: (2020)

Tract-based white matter hyperintensity patterns in patients with systemic lupus erythematosus using an unsupervised machine learning approach
por: Rumetshofer, Theodor, et al.
Publicado: (2022)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Neutrino Masses and Mixing: Where We Stand and Where We are Going
por: Gonzalez-Garcia, M.C.
Publicado: (2002)

Alzheimer’s disease and infections, where we stand and where we go
por: Monastero, Roberto, et al.
Publicado: (2014)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Establishment of Fracture Liaison Service in Korea: Where Is It Stand and Where Is It Going?
por: Cha, Yong Han, et al.
Publicado: (2019)

Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activity
por: Monahan, Rory C, et al.
Publicado: (2021)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Sympathetic Modulation in Cardiac Arrhythmias: Where We Stand and Where We Go
por: Chung, Wei-Hsin, et al.
Publicado: (2023)

Longitudinal changes in cerebral white matter microstructure in newly diagnosed systemic lupus erythematosus patients
por: Silvagni, Ettore, et al.
Publicado: (2020)

Nature and nurture in neuropsychiatric genetics: where do we stand?
por: Dick, Danielle M., et al.
Publicado: (2010)

Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
por: Ziegelasch, Michael, et al.
Publicado: (2016)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
por: Agapidou, Alexandra, et al.
Publicado: (2016)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
por: Laine, Christopher G., et al.
Publicado: (2020)

Drug misuse in India: Where do we stand & where to go from here?
por: Avasthi, Ajit, et al.
Publicado: (2019)

Late Sodium Current of the Heart: Where Do We Stand and Where Are We Going?
por: Horváth, Balázs, et al.
Publicado: (2022)

EEG Recordings as Biomarkers of Pain Perception: Where Do We Stand and Where to Go?
por: Zis, Panagiotis, et al.
Publicado: (2022)

Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands
por: Monahan, Rory C, et al.
Publicado: (2020)

Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going
por: Risitano, Antonio M
Publicado: (2014)

Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?
por: Banz-Jansen, Constanze, et al.
Publicado: (2022)

Structural and functional genomics in Old World camels—where do we stand and where to go
por: Burger, Pamela A, et al.
Publicado: (2022)

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
por: Harari, Sergio, et al.
Publicado: (2015)

Commentary: Automation of laboratory instrumentation: where is it going?
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_d3vnv9f9hn7s54c28e7lodnuv4